Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 3
2004 3
2005 2
2006 1
2007 3
2008 4
2010 2
2011 2
2012 3
2013 3
2018 2
2019 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

31 results
Results by year
Filters applied: . Clear all
Page 1
Galiximab: a review.
Bhat S, Czuczman MS. Bhat S, et al. Expert Opin Biol Ther. 2010 Mar;10(3):451-8. doi: 10.1517/14712591003596318. Expert Opin Biol Ther. 2010. PMID: 20092425 Review.
WHAT THE READER WILL GAIN: Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab. An update of currently available clinical data will be presented. TAKE HOME MESSAGE: Data from completed clinical trials are promising a …
WHAT THE READER WILL GAIN: Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab
The use of galiximab in non-Hodgkin lymphoma.
Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. Vinjamaram S, et al. Clin Lymphoma Myeloma. 2008 Oct;8(5):277-82. doi: 10.3816/CLM.2008.n.038. Clin Lymphoma Myeloma. 2008. PMID: 18854281 Review.
An initial phase I/II study with galiximab as a single agent in patients with relapsed B-cell lymphoma demonstrated its safety and antitumor activity and had provided a framework for future studies. ...Ongoing and future studies are warranted to further evaluate the therap …
An initial phase I/II study with galiximab as a single agent in patients with relapsed B-cell lymphoma demonstrated its safety and an …
Galiximab signals B-NHL cells and inhibits the activities of NF-kappaB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Baritaki S, Vega GG, Hariharan K, Bonavida B. Martinez-Paniagua MA, et al. Mol Cancer Ther. 2012 Mar;11(3):572-81. doi: 10.1158/1535-7163.MCT-11-0635. Epub 2012 Jan 19. Mol Cancer Ther. 2012. PMID: 22267549 Free article.
Galiximab inhibits tumor cell proliferation through possibly cell signaling-mediated effects. ...Treatment of B-NHL cells with galiximab sensitized the tumor cells to both cis-diamminedichloroplatinum(II) (CDDP)- and TRAIL-induced apoptosis. ...
Galiximab inhibits tumor cell proliferation through possibly cell signaling-mediated effects. ...Treatment of B-NHL cells with gal
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Hariharan K, Chu P, Murphy T, Clanton D, Berquist L, Molina A, Ho SN, Vega MI, Bonavida B. Hariharan K, et al. Int J Oncol. 2013 Aug;43(2):670-6. doi: 10.3892/ijo.2013.1986. Epub 2013 Jun 13. Int J Oncol. 2013. PMID: 23764770 Free PMC article.
Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as a potential treatment for follicular NHL. ...Tumor growth inhibition was significantly enhanced when the mice were treated with the combinat
Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Czuczman MS, et al. J Clin Oncol. 2005 Jul 1;23(19):4390-8. doi: 10.1200/JCO.2005.09.018. J Clin Oncol. 2005. PMID: 15994148 Clinical Trial.
RESULTS: Thirty-seven patients received galiximab treatment and were evaluated for safety; 35 were assessable for response. ...Two responders remain on study without progression (22 and 24.4 months). CONCLUSION: The favorable safety profile of galiximab and evidence …
RESULTS: Thirty-seven patients received galiximab treatment and were evaluated for safety; 35 were assessable for response. ...Two re …
Galiximab in relapsed hodgkin lymphoma.
Smith SM. Smith SM. Clin Adv Hematol Oncol. 2010 Oct;8(10):669-70. Clin Adv Hematol Oncol. 2010. PMID: 21317862 No abstract available.
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. Leonard JP, et al. Ann Oncol. 2007 Jul;18(7):1216-23. doi: 10.1093/annonc/mdm114. Epub 2007 Apr 29. Ann Oncol. 2007. PMID: 17470451 Free article. Clinical Trial.
BACKGROUND: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and other lymphomas. ...Combination therapy did not appear to alter pharmacokinetics. CONCLUSION: These results indicate that galiximab
BACKGROUND: Galiximab is a monoclonal antibody that targets CD80, a costimulatory molecule constitutively expressed on follicular and …
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM, Schöder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD; Alliance for Clinical Trials in Oncology. Smith SM, et al. Leuk Lymphoma. 2013 Jul;54(7):1405-10. doi: 10.3109/10428194.2012.744453. Epub 2013 Jan 4. Leuk Lymphoma. 2013. PMID: 23194022 Free PMC article. Clinical Trial.
The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minimal grade 3 or 4 toxicities. Despite this preclinical rationale, single-agent galiximab had limited activity in heavily pretreated Hod …
The overall response rate was 10.3% and the median progression-free survival was 1.6 months. Galiximab was well-tolerated, with minim …
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC. Gottlieb AB, et al. Clin Immunol. 2004 Apr;111(1):28-37. doi: 10.1016/j.clim.2004.01.006. Clin Immunol. 2004. PMID: 15093549 Clinical Trial.
METHODS: Seven cohorts of five patients received galiximab intravenously on three different schedules at different dose levels. ...An association was observed between reduction in CD3(+) cell count in histologic studies and reduction in PASI score. No antibodies to gali
METHODS: Seven cohorts of five patients received galiximab intravenously on three different schedules at different dose levels. ...An …
31 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page